BCTX - BriaCell Therapeutics Corp. News

Sectors

BCTX

BriaCell Therapeutics Corp.

3.71

1 x 3.65

1 x 3.96

bid

ask

0.04

1.20%

10:01 AM

timesize

Ytd	-47.89%
1y	-53.98%

3.65

day range

3.74

2.60

52 week range

14.68

Open	3.74	Prev Close	3.75	Low	3.65	High	3.74	Mkt Cap	7.06M
Vol	12.28K	Avg Vol	208.59K	EPS	-18.41	P/E	-0.20	Forward P/E	-1.38
Beta	1.15	Short Ratio	0.77	Inst. Own	4.65%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	06-16	50-d Avg	3.41	200-d Avg	6.13	1yr Est	15.00

BCTX News

globenewswire.com

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Can

PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic

benzinga.com

BriaCell Therapeutics Enters Manufacturing Arrangement With FUJIFILM Biotechnologies To Support Phas

Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination

globenewswire.com

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic

benzinga.com

BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Marke

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company&

globenewswire.com

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of

PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic

benzinga.com

BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle T

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company&

globenewswire.com

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

PHILADELPHIA and VANCOUVER, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic

globenewswire.com

BriaCell Therapeutics Announces Closing of Offering

PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics

globenewswire.com

BriaCell Presents Positive Clinical Data at ASCO 2026

Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metast

globenewswire.com

BriaCell Therapeutics Announces Pricing of Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics

globenewswire.com

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study

PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics

globenewswire.com

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics

globenewswire.com

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast c

globenewswire.com

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics

globenewswire.com

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Canc

PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics

globenewswire.com

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics

globenewswire.com

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Brea

PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics

globenewswire.com

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinic

globenewswire.com

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti

globenewswire.com

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

PHILADELPHIA and VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti

globenewswire.com

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeti

PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti

defenseworld.net

Briacell Therap (NASDAQ:BCTX) Short Interest Update

Briacell Therap (NASDAQ: BCTX - Get Free Report) was the recipient of a large increase in short inte

globenewswire.com

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 Licen

PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti

benzinga.com

Glaukos, Trip.com Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com

Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket